Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, Ontario, Nov. 25 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: "HBP")\nhas filed a Form 20-F Registration Statement with the United States Securities\nand Exchange Commission, to register its common shares with the SEC.\n\n\n\n\n\nA Form 20-F, once declared effective by the SEC, allows certain foreign\ncorporations to register securities with the SEC pursuant to Section 12(g) of\nthe Securities Exchange Act of 1934, as amended. The Company's Form 20-F is a\nfull registration of the Company's common shares with the SEC as a foreign\nprivate issuer similar to a Form 10 filing for a domestic issuer in the United\nStates. The Company's registration of its shares in the United States would\nallow its shares to be solicited and traded by licensed brokers in the United\nStates in compliance with SEC regulations and blue sky requirements in various\nstates in the United States.\n\n\n\n\n\n"Today's filing is a significant step for the Company toward our goal to\nenter larger capital markets," said John Docherty, president of Helix\nBioPharma. "Following effectiveness, we intend to expand our ongoing efforts\nto grow Helix's corporate profile, with a view to broadening our U.S. investor\nbase and increasing our liquidity."\n\n\n\n\n\nThe Form 20-F is being filed on EDGAR and SEDAR at\nwww.sec.gov/edgar.shtml and www.sedar.com, respectively. Helix anticipates the\nForm 20-F will be declared effective by the SEC in early 2009, although there\nis no guarantee that the SEC will declare the filing effective. If the Form\n20-F is declared effective by the SEC, the Company will be obligated to file\ncontinuous disclosure documentation applicable to foreign private issuers with\nthe SEC following the date the Form 20-F is declared effective.\n\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP."\n\n\nFor further information contact:\n\n\nInvestor & Media Relations\nIan Stone Robert Flamm, Ph.D.\nRusso...

More updates from Helix Biopharma Corp.